Latest Regulatory Framework News

Adherium Limited secured shareholder approval for all resolutions at its June 19, 2026 Extraordinary General Meeting, including a pivotal 1-for-100 share consolidation and approvals tied to recent capital raises and director participation.

Cobalt Blue Holdings and Glomar Minerals have shortlisted four US sites and begun testwork for Project Infinity, aiming to build the first commercial polymetallic nodule refinery in the United States.

Midas Minerals extends high-grade copper and silver intercepts at Namibia’s T-13 deposit, reinforcing resource continuity ahead of a planned update later this year.

Brazilian Critical Minerals (ASX: BCM) has cleared a major regulatory hurdle as Brazil's Federal Mines Agency approves the final exploration reports for its Ema rare earth project, paving the way for mining license applications and further development.

Horizon Oil has lifted all but one condition from its off-market bid for Cue Energy, maintaining a controlling 52.46% stake while the final hurdle over prescribed occurrences remains unresolved.

The Primary Court of Ibra in Oman has dismissed all substantive legal claims against Alara Resources' joint venture, affirming the validity of permits and licences for the Al Wash-hi Majaza mine and allowing operations to continue unimpeded.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

Novo Resources has delivered a maiden inferred resource estimate for the Leven Star Reef within its Belltopper Gold Project, outlining 87,000 ounces of contained gold and setting the stage for further exploration and resource expansion.

Hammer Metals (ASX:HMX) has voluntarily suspended trading of its shares pending an announcement about a potential material corporate transaction that could change control of the company.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

Santana Minerals' Bendigo-Ophir Gold Project has entered the hearing phase of its regulatory assessment, with concurrent technical hearings scheduled for June and a statutory decision due by late October 2026.